Trial Profile
Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Interferon beta (Primary) ; MCPyV TAg specific t cell vaccine (Primary)
- Indications Merkel cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 06 Jun 2017 Results assessing the augmentation of adoptive T-cell therapy in patients from two related phase I/II trials (NCT01758458 and NCT02584829; n=8), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 01 Feb 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 23 Jan 2013 New trial record